The global Peptide and Oligonucleotide CDMO (Contract Development and Manufacturing Organization) Market is undergoing a major transformation, driven by the expanding clinical pipeline of nucleic acid-based drugs and peptide therapies. As the pharmaceutical industry continues to shift its focus toward precision medicine, outsourcing of complex development and manufacturing activities has emerged as a strategic imperative.
Global Peptide and Oligonucleotide CDMO Market size and share is currently valued at USD 2,078.37 million in 2024 and is anticipated to generate an estimated revenue of USD 4,646.57 million by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 10.6% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024 - 2032
Market Overview
Peptides and oligonucleotides are two of the fastest-growing therapeutic modalities in the pharmaceutical landscape. Their unique molecular properties enable targeted treatment approaches, especially in the fields of oncology, rare diseases, genetic disorders, and metabolic conditions. However, the complexity and cost of developing and manufacturing these molecules in-house have driven both large pharmaceutical companies and small biotech firms to outsource these functions to specialized CDMOs.
Custom peptide synthesis requires precise processes and specialized equipment to ensure high purity and therapeutic efficacy. Meanwhile, oligonucleotide therapeutics—such as siRNAs, antisense oligonucleotides, and mRNA—demand sophisticated synthesis, purification, and GMP manufacturing environments to meet stringent regulatory and safety standards.
CDMOs that offer integrated development, scale-up, and manufacturing capabilities across peptides and nucleic acids are becoming indispensable to the global drug development ecosystem.
Country-Wise Market Trends Analysis
To understand the evolving dynamics of the Peptide and Oligonucleotide CDMO Market, a country-wise analysis provides insights into investment trends, regulatory developments, and innovation activity shaping demand.
United States
The U.S. represents the largest share of the global market, with a highly mature biotech ecosystem and strong government funding for research in nucleic acid-based drugs. The country continues to witness an increasing number of clinical trials involving peptide and RNA-based therapies.
Key market trends include:
-
Rapid expansion of mRNA and antisense oligonucleotide research post-COVID.
-
Growing use of GMP manufacturing services for investigational new drugs (INDs).
-
Increasing partnerships between small biotech firms and CDMOs to accelerate drug development.
With favorable regulatory pathways such as fast-track and orphan drug designations, the demand for CDMO services in the U.S. is anticipated to remain robust over the next decade.
Browse Full Insights:
https://www.polarismarketresearch.com/industry-analysis/peptide-and-oligonucleotide-cdmo-market
Germany
Germany stands as a European leader in pharmaceutical R&D, with a long-established manufacturing base and academic excellence in molecular biology.
Trends shaping the German market:
-
Strong emphasis on custom peptide synthesis for applications in endocrinology and oncology.
-
Adoption of green and sustainable chemistry practices in CDMO operations.
-
Government funding initiatives to support RNA-based research and manufacturing infrastructure.
Germany’s regulatory focus on product safety and quality has led to high demand for CDMOs with end-to-end GMP-compliant processes.
China
China is rapidly gaining ground as both a consumer and provider of CDMO services. With continued investment in biopharmaceutical innovation and manufacturing, the country is becoming a hub for peptide and nucleic acid drug development.
Key developments:
-
Major expansion in local manufacturing capacity for oligonucleotide therapeutics.
-
Favorable policies supporting biotech startups through tax incentives and grants.
-
Initiatives to attract global clinical trials and CDMO partnerships.
China's growing domestic demand for advanced therapies is expected to elevate its role in the global CDMO value chain.
Japan
Japan has a strong pharmaceutical industry and a population with a high burden of chronic diseases—both of which drive demand for innovative treatment modalities.
Current trends include:
-
Increased clinical research on nucleic acid-based drugs, particularly in genetic eye disorders and neurological diseases.
-
National initiatives to improve biologics manufacturing capacity.
-
A shift from traditional small-molecule APIs toward specialized biologics and peptides.
Japan’s stringent regulatory landscape places a premium on GMP manufacturing, positioning CDMOs as vital players in drug lifecycle management.
India
India has emerged as a cost-effective destination for pharmaceutical development, and it is gradually building a presence in the peptide and oligonucleotide segment.
Trends influencing market growth:
-
A growing talent pool of chemists and biotechnologists skilled in custom peptide synthesis.
-
Expansion of facilities with GMP and regulatory certifications for global exports.
-
Increasing engagement with multinational pharma for early-phase development services.
India’s affordability and compliance improvements are attracting projects from the U.S., EU, and Japan.
United Kingdom
Post-Brexit, the UK has reinforced its position as a center for innovation in biotech, with a focus on rare diseases and RNA-based therapeutics.
Emerging patterns include:
-
A strong focus on early-phase development for oligonucleotide therapeutics.
-
Collaboration between academic institutions and CDMOs for clinical translation.
-
Development of regional clusters supporting life sciences manufacturing.
The UK’s regulatory clarity and investment in next-gen therapies make it a competitive CDMO market.
South Korea
South Korea is expanding its presence in advanced therapeutics, supported by government-led initiatives to become a global biotech hub.
Notable trends:
-
Public-private partnerships to boost peptide and mRNA drug production.
-
Investments in AI-driven bioprocess optimization for CDMO services.
-
Growing demand for GMP manufacturing services aligned with international standards.
The country’s rapid technology adoption and supportive infrastructure are catalyzing CDMO sector growth.
Canada
Canada’s biopharmaceutical sector is gaining momentum, supported by a stable regulatory environment and a strong academic foundation.
Market trends in Canada include:
-
Increased funding for clinical research in nucleic acid-based drugs.
-
Interest in boutique CDMOs offering high-value peptide services.
-
Supportive ecosystem for early-phase R&D and translational science.
Canada is expected to benefit from North American collaborations and export opportunities.
Australia
Australia is becoming a key destination for early-stage trials, driven by favorable regulatory timelines and tax incentives.
Key observations:
-
Rising demand for custom peptide synthesis services for oncology and metabolic disorders.
-
Government support for RNA and peptide drug development via innovation grants.
-
Integration of research institutes with industry accelerators.
Australia’s unique position allows it to attract biotech firms seeking rapid trial deployment and CDMO engagement.
Brazil
Brazil represents Latin America’s most developed pharmaceutical market, with a growing interest in biologics and advanced therapies.
Ongoing trends:
-
Increasing government investment in local drug manufacturing infrastructure.
-
Partnerships between global CDMOs and Brazilian research institutions.
-
Growth in demand for GMP manufacturing of investigational peptide drugs.
As the region’s regulatory landscape evolves, Brazil is expected to play a larger role in regional CDMO services.
Conclusion
The global Peptide and Oligonucleotide CDMO Market is entering a high-growth phase, driven by the therapeutic potential of nucleic acid-based drugs and the need for precision therapies across diseases. As countries across the globe invest in biotechnology infrastructure, strengthen regulatory frameworks, and encourage innovation, the demand for specialized services such as custom peptide synthesis, oligonucleotide therapeutics, and GMP manufacturing is expected to rise exponentially.
Each country presents a unique combination of strengths and strategic priorities—from innovation hubs in the U.S. and Europe to cost-effective scaling in Asia and emerging research landscapes in Latin America. CDMOs that can adapt to these localized demands while maintaining global quality standards will be essential partners in accelerating the future of medicine.
More Trending Latest Reports By Polaris Market Research:
Voluntary Carbon Credit Market
Trivalent Chromium Finishing Market
Southeast Asia Wood Pellet Market
Pipeline Monitoring System Market
English
Arabic
French
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek